Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidence

被引：27
|
作者：
Akazawa, Yuko [1 ]
Fukuda, Daisuke [2 ]
Fukuda, Yutaka [2 ]
机构：
[1] Nagasaki Univ Hosp, Dept Gastroenterol & Hepatol, 1-7-1 Sakamoto, Nagasaki 8528501, Japan
[2] Fukuda Yutaka Surg Clin, Nagasaki, Japan
来源：
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY | 2016年 / 9卷 / 06期
关键词：
Vonoprazan; H; pylori; PPI; Takecab; potassium-competitive acid blocker; P-CAB; TAK-438; COMPETITIVE ACID BLOCKER; TRIPLE THERAPY; TAK-438; VONOPRAZAN; GASTRIC-CANCER; CLARITHROMYCIN; EFFICACY; TOLERABILITY; RESISTANCE; INFECTION; SAFETY;
D O I：
10.1177/1756283X16668093
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Stable suppression of gastric acid secretion is a crucial factor in Helicobacter pylori eradication. Vonoprazan is a potassium-competitive acid blocker recently approved for use in Japan. As vonoprazan has a long duration of action and causes rapid and strong inhibition of gastric acid secretion, it has gained clinical attention for treating erosive oesophagitis, peptic ulcers, and H. pylori infection. In this review, we discuss the recent knowledge regarding the safety and efficacy of vonoprazan, focusing on its use in H. pylori eradication. The latest literature and our clinical experience have shown that vonoprazan-based therapies have satisfactory eradication rates. Additionally, vonoprazan-based therapies are associated with similar rates of adverse events as standard triple therapies with conventional proton-pump inhibitors.
引用
收藏
页码：845 / 852
页数：8
相关论文
共 50 条
  • [21] Efficacy and safety of vonoprazan-based regimen for Helicobacter pylori eradication therapy in Japanese adolescents: a prospective multicenter study
    Kakiuchi, Toshihiko
    Matsuo, Muneaki
    Endo, Hiroyoshi
    Sakata, Yasuhisa
    Esaki, Motohiro
    Noda, Takahiro
    Imamura, Ichiro
    Hashiguchi, Kazutoshi
    Ogata, Shinichi
    Fujioka, Yasuhiko
    Hanada, Keiichiro
    Fukuda, Kayoko
    Yoshimura, Masaya
    Kajiwara, Tetsuro
    Yamamoto, Kentaroh
    Yamaguchi, Daisuke
    Kawakubo, Hiroharu
    Matsunaga, Takuya
    Sumino, Michihiro
    Matsunaga, Keiji
    Muro, Eriko
    Watanabe, Akira
    Fujimoto, Kazuma
    JOURNAL OF GASTROENTEROLOGY, 2023, 58 (03) : 196 - 204
  • [22] Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication
    Jung, Y. S.
    Kim, E. H.
    Park, C. H.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (02) : 106 - 114
  • [23] Vonoprazan-Based Triple-Therapy Could Improve Efficacy of the Tailored Therapy of Helicobacter pylori Infection
    Shinmura, Tetsuya
    Adachi, Kazunori
    Yamaguchi, Yoshiharu
    Izawa, Shinya
    Hijikata, Yasutaka
    Ebi, Masahide
    Funaki, Yasushi
    Ogasawara, Naotaka
    Sasaki, Makoto
    Kasugai, Kunio
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2019, 28 (04) : 389 - 395
  • [24] Vonoprazan on the Eradication of Helicobacter pylori Infection
    Huang, Jiaming
    Lin, Ye
    TURKISH JOURNAL OF GASTROENTEROLOGY, 2023, 34 (03) : 221 - 226
  • [25] Clinical Study on the Eradication of Helicobacter pylori by Vonoprazan Combined with Amoxicillin for 10-Day Dual Therapy
    Yan, Kunfeng
    Dai, Xiaorong
    Li, Zhenxing
    Rong, Weiwei
    Chen, Lei
    Diao, Xinxin
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2024, 13 (03): : 240 - 247
  • [26] The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication
    Sue, Soichiro
    Kuwashima, Hirofumi
    Iwata, Yuri
    Oka, Hiroyuki
    Arima, Isao
    Fukuchi, Takehide
    Sanga, Katsuyuki
    Inokuchi, Yasuhiro
    Ishii, Yuniba
    Kanno, Masatomo
    Terada, Masahiro
    Amano, Hitoshi
    Naito, Makoto
    Iwase, Shigeru
    Okazaki, Hiroshi
    Komatsu, Kazuto
    Kokawa, Atsushi
    Kawana, Ichiro
    Morimoto, Manabu
    Saito, Toshifumi
    Kunishi, Yosuke
    Ikeda, Akihiko
    Takahashi, Daisuke
    Miwa, Haruo
    Sasaki, Tomohiko
    Tamura, Toshihide
    Kondo, Masaaki
    Shibata, Wataru
    Maeda, Shin
    INTERNAL MEDICINE, 2017, 56 (11) : 1277 - 1285
  • [27] Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication
    Kusunoki, Maho
    Yuki, Mika
    Ishitobi, Hitomi
    Kobayashi, Yoshiya
    Nagaoka, Makoto
    Takahashi, Yoshiko
    Fukuba, Nobuhiko
    Komazawa, Yoshinori
    Shizuku, Toshihiro
    Kinoshita, Yoshikazu
    INTERNAL MEDICINE, 2019, 58 (11) : 1549 - 1555
  • [28] Efficacy of vonoprazan-based second-line Helicobacter pylori eradication therapy in patients for whom vonoprazan-based first-line treatment failed
    Katayama, Yasumi
    Toyoda, Kouji
    Kusano, Yuumi
    Suda, Toshikuni
    Adachi, Shogo
    Terauchi, Itsuo
    Oka, Shigeki
    Takahashi, Morio
    Tamano, Masaya
    GUT, 2017, 66 (04) : 752 - 753
  • [29] Prospective Study of Vonoprazan-Based First-Line Triple Therapy with Amoxicillin and Metronidazole for Clarithromycin-Resistant Helicobacter pylori
    Sue, Soichiro
    Suzuki, Yuichi
    Sasaki, Tomohiko
    Kaneko, Hiroaki
    Irie, Kuniyasu
    Komatsu, Kazuto
    Maeda, Shin
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (17)
  • [30] Pre-treatment with proton pump inhibitors decreases the success of primary Helicobacter pylori eradication using a vonoprazan-based regimen
    Shinozaki, Satoshi
    Osawa, Hiroyuki
    Sakamoto, Hirotsugu
    Hayashi, Yoshikazu
    Kobayashi, Yasutoshi
    Miura, Yoshimasa
    Lefor, Alan Kawarai
    Yamamoto, Hironori
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2018, 34 (08) : 456 - 460
12345